Tyr18
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr18  -  CSK (mouse)

Site Information
GTECIAKyNFHGTAE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 41510404

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
leukemia ( 1 ) , T cell leukemia ( 1 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 1 ) , Jurkat (T lymphocyte) ( 1 ) , mononuclear-blood ( 1 ) , spleen ( 1 )

Upstream Regulation
Putative in vivo kinases:
Ack (human) ( 1 )
Treatments:
(R)-9bMS ( 1 ) , antibody ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on CSK:
enzymatic activity, induced ( 1 ) , phosphorylation ( 1 ) , protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 )

References 

1

Sridaran D, et al. (2022) Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat Commun 13, 6929
36376335   Curated Info

PhosphoSitePlus® is a registered trademark of Cell Signaling Technology.
Use of PSP data is subject to a formal license agreement. Learn more

©2003-2025 Cell Signaling Technology, Inc.